Key Highlights
- Lantern Pharma Publicly Releases PredictBBB.ai, an Advanced AI Module for Blood-Brain Barrier Permeability Prediction
The platform achieves unprecedented 94% accuracy, 95% sensitivity, and 89% specificity using a large-scale molecular data lake and real-time ensemble machine learning. - Freemium Access Model Democratizes Critical CNS Drug Development Technology Globally
This strategy accelerates adoption and strategic collaborations, aiming to transform drug development economics and success rates for brain-targeting therapies. - Integrated with the RADR AI Platform, Enabling Broader Molecular and Clinical Insights for Oncology and CNS Programs
Lantern plans rapid future rollout of additional predictive modules leveraging the same AI architecture, expanding impact across diverse therapeutic areas.
Breakthrough AI Methodology Sets New Industry Benchmark
Lantern’s proprietary ensemble of machine learning algorithms—including logistic regression, random forests, SVMs, and deep neural networks—process billions of molecular features across millions of compounds with real-time scalability. This integrated architecture delivers the highest accuracy and fast predictions critical for early CNS drug candidate evaluation.
Transforming CNS Drug Discovery Economics and Outcomes
By accurately predicting blood-brain barrier permeability—a historic bottleneck in CNS drug development—predictBBB.ai reduces costly late-stage failures and accelerates therapeutic innovation for neurological diseases and brain cancers.
Strategic Freemium Market Approach to Empower Researchers Worldwide
Offering foundational BBB prediction capabilities for free with options for advanced features, Lantern is stimulating broad adoption while building value-driven partnerships to expand its AI-powered drug discovery ecosystem.
Strong Intellectual Property Protection and Future Expansion Plans
Lantern’s PCT patent application ensures competitive advantage and market exclusivity for 20 years, supporting continued platform evolution. Upcoming modules will target dozens of critical molecular properties to create a comprehensive AI discovery toolkit.
For more information, visit www.predictBBB.ai or www.lanternpharma.com.
By